Intermediate-term oncological and functional outcomes of salvage cryotherapy for the management of prostate cancer recurrence after primary brachytherapy versus primary cryotherapy: A propensity score-matched analysis.
Male
Humans
Brachytherapy
/ adverse effects
Erectile Dysfunction
/ etiology
Prostate-Specific Antigen
Retrospective Studies
Propensity Score
Neoplasm Recurrence, Local
/ radiotherapy
Prostatic Neoplasms
/ radiotherapy
Cryotherapy
/ adverse effects
Fistula
/ etiology
Salvage Therapy
Treatment Outcome
biochemical recurrence
brachytherapy
cryotherapy
functional outcomes
oncological outcomes
prostate cancer
salvage therapy
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
18
06
2023
received:
11
05
2023
accepted:
10
07
2023
medline:
28
8
2023
pubmed:
20
7
2023
entrez:
20
7
2023
Statut:
ppublish
Résumé
Salvage cryotherapy (SCT) is widely used to treat prostate cancer (PCa) recurrence after radiotherapy (RT). We studied the intermediate oncological and functional outcomes of patients who underwent SCT following cryotherapy (CRYO-SCT) recurrence and compare it to recurrence after brachytherapy (BT-SCT). An IRB-approved retrospective cohort study utilizing patient data from the Cryo On-Line Data Registry and the Duke PCa database between 1992 and 2016. Biochemical recurrence (BCR) using Phoenix criteria was the primary endpoint assessed at 2- and 5-years post-SCT. Secondary endpoints assessed functional outcomes including urinary continence, erectile function, and recto-urethral fistula. Association between treatment and biochemical progression-free survival was assessed using inverse probability weighted (IPTW) Cox proportional hazards regression. The differences in the secondary functional outcomes were assessed by Pearson's χ A total of 194 patients met inclusion criteria. The BCR rate for BT-SCT and CRYO-SCT was 23 (20.4%) and 17 (21%) at 2 years and 30 (26.5%) and 22 (27.2%) at 5 years according to Phoenix criteria. There was no statistical difference in 2 years (hazard ratio [HR] 0.9; 95% confidence interval [CI], 0.5-1.7, p = 0.7) or 5-year BCR (HR: 0.86; 95% CI, 0.5-1.5, p = 0.6) between the groups. The functional outcomes like urinary continence (p = 0.4), erectile function (p = 0.1), and recto-urethral fistula (p = 0.3) were not statistically different. CRYO-SCT appears to be well tolerated, with comparable oncological and functional outcomes to patients failing primary BT. The findings also demonstrated that SCT can render a significant number of patients biochemically free of disease after initial CRYO with minimal morbidity. SCT is a viable treatment option to salvage local PCa recurrence following either BT or cryoablation failure.
Sections du résumé
BACKGROUND
Salvage cryotherapy (SCT) is widely used to treat prostate cancer (PCa) recurrence after radiotherapy (RT). We studied the intermediate oncological and functional outcomes of patients who underwent SCT following cryotherapy (CRYO-SCT) recurrence and compare it to recurrence after brachytherapy (BT-SCT).
METHODS
An IRB-approved retrospective cohort study utilizing patient data from the Cryo On-Line Data Registry and the Duke PCa database between 1992 and 2016. Biochemical recurrence (BCR) using Phoenix criteria was the primary endpoint assessed at 2- and 5-years post-SCT. Secondary endpoints assessed functional outcomes including urinary continence, erectile function, and recto-urethral fistula. Association between treatment and biochemical progression-free survival was assessed using inverse probability weighted (IPTW) Cox proportional hazards regression. The differences in the secondary functional outcomes were assessed by Pearson's χ
RESULTS
A total of 194 patients met inclusion criteria. The BCR rate for BT-SCT and CRYO-SCT was 23 (20.4%) and 17 (21%) at 2 years and 30 (26.5%) and 22 (27.2%) at 5 years according to Phoenix criteria. There was no statistical difference in 2 years (hazard ratio [HR] 0.9; 95% confidence interval [CI], 0.5-1.7, p = 0.7) or 5-year BCR (HR: 0.86; 95% CI, 0.5-1.5, p = 0.6) between the groups. The functional outcomes like urinary continence (p = 0.4), erectile function (p = 0.1), and recto-urethral fistula (p = 0.3) were not statistically different.
CONCLUSION
CRYO-SCT appears to be well tolerated, with comparable oncological and functional outcomes to patients failing primary BT. The findings also demonstrated that SCT can render a significant number of patients biochemically free of disease after initial CRYO with minimal morbidity. SCT is a viable treatment option to salvage local PCa recurrence following either BT or cryoablation failure.
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1373-1386Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/caac.21708
Jones JS. Radiorecurrent prostate cancer: an emerging and largely mismanaged epidemic. Eur Urol. 2011;60(3):411-412. doi:10.1016/j.eururo.2011.01.007
Suárez JF, Zamora V, Garin O, et al. Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study. Sci Rep. 2022;12(1):12589. doi:10.1038/s41598-022-16395-w
Xuan H, Lyu Y, Tao J, et al. Long-term prognosis and prognostic factors of brachytherapy and propensity score matched comparisons of the outcomes between brachytherapy and radical prostatectomy: a retrospective cohort study. Transl Androl Urol. 2022;11(12):1735-1746. doi:10.21037/tau-22-755
Donnelly BJ, Saliken JC, Brasher PMA, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer. 2010;116(2):323-330. doi:10.1002/cncr.24779
Oishi M, Gill IS, Ashrafi AN, et al. Primary whole-gland cryoablation for prostate cancer: biochemical failure and clinical recurrence at 5.6 years of follow-up. Eur Urol. 2019;75(2):208-214. doi:10.1016/j.eururo.2018.09.004
Tan WP, Kotamarti S, Chen E, et al. Oncological and functional outcomes of men undergoing primary whole gland cryoablation of the prostate: a 20-year experience. Cancer. 2022;128:3824-3830. doi:10.1002/cncr.34458
Cohen JK, Miller Jr. RJ, Ahmed S, Lotz MJ, Baust J. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology. 2008;71(3):515-518. doi:10.1016/j.urology.2007.09.059
Levy DA, Ross AE, ElShafei A, Krishnan N, Hatem A, Jones JS. Definition of biochemical success following primary whole gland prostate cryoablation. J Urol. 2014;192(5):1380-1384. doi:10.1016/j.juro.2014.05.003
Ward JF, DiBlasio CJ, Williams C, Given R, Jones JS. Cryoablation for locally advanced clinical stage T3 prostate cancer: a report from the Cryo-On-Line database (COLD) registry: cryoablation for CT3 prostate cancer. BJU Int. 2014;113(5):714-718. doi:10.1111/bju.12476
Valle LF, Lehrer EJ, Markovic D, et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol. 2021;80(3):280-292. doi:10.1016/j.eururo.2020.11.010
Chin YF, Lynn N. Systematic review of focal and salvage cryotherapy for prostate cancer. Cureus. 2022;14(6):26400. doi:10.7759/cureus.26400
Tan WP, Kotamarti S, Ayala A, et al. Oncological and functional outcomes for men undergoing salvage whole-gland cryoablation for radiation-resistant prostate cancer. Eur Urol Oncol. 2023;6:289-294. doi:10.1016/j.euo.2023.02.007
Aminsharifi A, Jibara G, Tsivian E, Tsivian M, Elshafei A, Polascik TJ. Salvage prostate cryoablation for the management of local recurrence after primary cryotherapy: aretrospective analysis of functional and intermediate-term oncological outcomes associated with a second therapeutic freeze. Clin Genitourin Cancer. 2019;17(4-e831-e836. doi:10.1016/j.clgc.2019.05.014
Chang P, Szymanski KM, Dunn RL, et al. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011;186(3):865-872. doi:10.1016/j.juro.2011.04.085
Rosen R, Cappelleri J, Smith M, Lipsky J, Peña B. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impotence Res. 1999;11(6):319-326. doi:10.1038/sj.ijir.3900472
Punnen S, Cooperberg MR, D'Amico AV, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2013;64(6):905-915. doi:10.1016/j.eururo.2013.05.025
Golbari NM, Katz AE. Salvage therapy options for local prostate cancer recurrence after primary radiotherapy: a literature review. Curr Urol Rep. 2017;18(8):63. doi:10.1007/s11934-017-0709-4
Gontero P, Marra G, Alessio P, et al. Salvage radical prostatectomy for recurrent prostate cancer: morbidity and functional outcomes from a large multicenter series of open versus robotic approaches. J Urol. 2019;202(4):725-731. doi:10.1097/ju.0000000000000327
Burton S, Brown DM, Colonias A, et al. Salvage radiotherapy for prostate cancer recurrence after cryosurgical ablation. Urology. 2000;56(5):833-838. doi:10.1016/s0090-4295(00)00778-0
McDonough MJ, Feldmeier JJ, Parsai I, Dobelbower Jr., RR, Selman SH. Salvage external beam radiotherapy for clinical failure after cryosurgery for prostate cancer. Int J Radiat Oncol Biol Phys. 2001;51(3):624-627. doi:10.1016/s0360-3016(01)01694-7
Hepel JT, MacAusland SG, Long JP, Wazer DE, DiPetrillo T. Intensity-modulated radiotherapy of the prostate after cryotherapy: initial experience. Urology. 2008;72(6):1310-1314. doi:10.1016/j.urology.2008.01.079
Choi M, Kim CR, Hung AY. Salvage intensity-modulated radiation therapy for locally recurrent prostate cancer after cryotherapy. Clin Genitourin Cancer. 2013;11(2):85-88. doi:10.1016/j.clgc.2012.09.003
Hopper AB, Sandhu APS, Parsons JK, Rose B, Einck JP. Salvage image guided radiation therapy to the prostate after cryotherapy failure. Adv Radiat Oncol. 2018;3(1):52-56. doi:10.1016/j.adro.2017.09.001
Nathan A, Fricker M, De Groote R, et al. Salvage versus primary robot-assisted radical prostatectomy: a propensity-matched comparative effectiveness study from a high-volume tertiary centre. Eur Urol Open Sci. 2021;27:43-52. doi:10.1016/j.euros.2021.03.003
Lee Cox R, David Crawford E. Complications of cryosurgical ablation of the prostate to treat localized adenocarcinoma of the prostate. Urology. 1995;45(6):932-935. doi:10.1016/s0090-4295(99)80110-1
Koppie TM, Shinohara K, Grossfeld GD, Presti Jr., JC, Carroll PR. The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience. J Urol. 1999;162(2):427-432.
Shinohara K. Prostate cancer: cryotherapy. Urol Clin North Am. 2003;30(4):725-736. doi:10.1016/s0094-0143(03)00065-x
Wenske S, Quarrier S, Katz AE. Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre. Eur Urol. 2013;64(1):1-7. doi:10.1016/j.eururo.2012.07.008
Chang X, Liu T, Zhang F, et al. Salvage cryosurgery for locally recurrent prostate cancer after primary cryotherapy. Int Urol Nephrol. 2015;47(2):301-305. doi:10.1007/s11255-014-0887-7